Full Text View
Tabular View
Study Results
Related Studies
Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)
This study has been completed.
Study NCT00680186   Information provided by Boehringer Ingelheim Pharmaceuticals

First Received on May 16, 2008.   Last Updated on September 12, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Thromboembolism
Additional conditions recognized in this trial
Venous Thromboembolism
Venous Thrombosis
More general conditions related to this trial
Cardiovascular Diseases
Embolism and Thrombosis
Thrombosis
Vascular Diseases
Interventions listed in this trial
Warfarin
Dabigatran etexilate
More general drug interventions related to this trial
Anticoagulants
Hematologic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Boehringer Ingelheim Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services